全球前列腺癌治療市場規模、佔有率、成長分析，依藥物（擠壓化療、生物療法）、配銷通路（醫院藥房、藥房和零售藥房）- 2024-2031 年行業預測

Global Prostate Cancer Treatment Market Size, Share, Growth Analysis, By Drug(Extruded Chemotherapy, Biological Therapy), By Distribution Channel(Hospitals Pharmacies, Drug Stores & Retail Pharmacies) - Industry Forecast 2024-2031

出版日期: 2024年02月27日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球前列腺癌治療市場規模為120億美元，預計將從2023年的130.4億美元成長到2031年的254.2億美元，預測期間（2024-2031年）複合CAGR為8.70%。

全球前列腺癌治療市場呈現出一個充滿活力的格局，伴隨著重要的市場洞察，這主要是由前列腺癌的盛行率所推動的，前列腺癌是全世界男性最常診斷的癌症之一。市場的主要目標是為患有這種疾病的個人提供先進且有效的治療選擇。多種因素推動了市場的成長，包括人口老化、意識的提高以及早期診斷工作促使新療法和藥物的開發。然而，市場遇到了一些限制，例如治療費用增加以及與前列腺癌治療相關的潛在副作用，這可能會阻礙廣泛採用。主要促進因素包括人口老化、前列腺癌發病率上升、藥物干預措施激增、對治療選擇的認知提高、研發資金增加、市場滲透率提高以及複雜管道藥物的出現以及創新療法的出現。此外，對前列腺癌治療的需求不斷成長，以及在非轉移性去勢抵抗性和轉移性荷爾蒙初治前列腺癌中使用荷爾蒙療法也有助於市場擴張。此外，發展中經濟體呈現出未開發的潛力，在預測期內提供了利潤豐厚的成長機會；然而，低度開發地區恢復期延長和前列腺癌藥物需求疲軟可能會阻礙市場成長。全球前列腺癌治療市場面臨的課題包括需要更有針對性的治療方法和不斷發展的監管框架。儘管如此，透過藥物標靶增強，該市場存在大量機會，隨著市場的不斷發展，這將顯著提高個別患者的治療精度。增加對研發工作的投資可能會促使開發出更有效的療法，從而提高前列腺癌患者的生活品質和存活率。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 歐洲其他地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 拉丁美洲其他地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- MEA 的其餘部分

競爭格局

前 5 名企業比較
2021 年關鍵參與者的市場定位
主要市場參與者所採取的策略
最佳制勝策略
近期市集活動
主要公司市佔率（%），2021年

主要公司簡介

Ferring Pharmaceuticals Inc. (Switzerland)
GlaxoSmithKline Plc. (UK)
Ipsen Pharma (France)
AstraZeneca plc (UK)
F. Hoffmann-La Roche AG (Switzerland)
Astellas Pharma Inc (Japan)
Johnson & Johnson (US)
Bayer AG. (Germany)
Bristol-Myers Squibb Company (US)
Takeda Pharmaceutical Company Ltd (Japan)
Amgen Inc. (US)
Pfizer Inc (US)
Novartis AG (Switzerland)
Sanofi (France)
Merck & Co., Inc (US)
Eli Lilly and Company (US)
Gilead Sciences, Inc (US)
AbbVie Inc (US)
Celgene Corporation (US)
Teva Pharmaceutical Industries Ltd (Israel)

簡介目錄

Product Code: SQMIG35I2244

Global Prostate Cancer Treatment Market size was valued at USD 12 billion in 2022 and is poised to grow from USD 13.04 billion in 2023 to USD 25.42 billion by 2031, growing at a CAGR of 8.70% in the forecast period (2024-2031).

The global market for prostate cancer treatment presents a dynamic landscape accompanied by crucial market insights, driven primarily by the prevalence of prostate cancer, one of the most commonly diagnosed cancers in men worldwide. The market's main objective revolves around offering advanced and efficacious treatment options for individuals afflicted with this condition. Various factors fuel market growth, including the aging population, heightened awareness, and early diagnosis efforts leading to the development of novel treatments and medications. Nevertheless, the market encounters constraints such as elevated treatment expenses and potential side effects associated with prostate cancer therapies, which could impede widespread adoption. Key drivers encompass the aging demographic, escalating incidence rates of prostate cancer, proliferation of pharmaceutical interventions, heightened awareness regarding treatment options, increased research and development funding, enhanced market penetration, and the emergence of sophisticated pipeline drugs alongside the availability of innovative therapies. Additionally, the rising demand for prostate cancer treatments and the utilization of hormonal therapy in non-metastatic castration-resistant and metastatic hormone-naive prostate cancer scenarios contribute to market expansion. Furthermore, developing economies present untapped potentials, offering lucrative growth opportunities during the forecast period; however, prolonged recovery periods in underdeveloped regions and subdued demand for prostate cancer drugs may hinder market growth. Challenges in the global prostate cancer treatment market include the necessity for a more tailored treatment approach and evolving regulatory frameworks. Nonetheless, substantial opportunities exist in this market through drug targeting enhancements, which significantly augment treatment precision for individual patients as the market continues to evolve. Increased investment in research and development endeavors could lead to the development of more effective therapies, thereby enhancing the quality of life and survival rates for prostate cancer patients.

Top-down and bottom-up approaches were used to estimate and validate the size of the Prostate Cancer Treatment Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Prostate Cancer Treatment Market Segmental Analysis

The global prostate cancer treatment market is segmented on the basis of drug, distribution channel, and region. By drug, the market is segmented into chemotherapy, biological therapy, hormone therapy, and others. By distribution channel, the market is segmented into hospitals pharmacies, drug stores & retail pharmacies, and online pharmacies. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Prostate Cancer Treatment Market

The rising prevalence of prostate cancer is driven by various factors, including an aging global population and improved diagnostic techniques, leading to increased awareness and earlier detection. As the incidence of prostate cancer is expected to rise, particularly among older men, there is a growing demand for effective treatment options in the global market.

Restraints in the Prostate Cancer Treatment Market

the market faces challenges such as high costs associated with targeted therapies and immunotherapies, which can pose affordability issues for patients and healthcare providers alike. Despite the promise of these advanced therapies in improving patient outcomes, access remains limited due to financial constraints. Addressing cost barriers is crucial to ensure widespread access to potentially life-saving treatments for prostate cancer.

Market Trends of the Prostate Cancer Treatment Market

A notable trend in the market is the adoption of personalized medicine approaches in prostate cancer treatment, which involves tailoring treatments based on individual genetic and molecular characteristics. This approach enhances treatment accuracy and reduces the risk of unnecessary interventions, thereby minimizing side effects and improving overall outcomes. Popular biochemical tests such as the Prostate Health Index (PHI), Oncotype DX Genomic Prostate Score, and Prolaris test are utilized to identify genetic variations in cancer cells, guiding treatment decisions. Targeted therapies like olaparib and rucaparib, which specifically target tumors with DNA repair process alterations, exemplify this personalized approach and demonstrate potential in treating advanced prostate cancer.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Prostate Cancer Treatment Market by Drug

Market Overview
Extruded Chemotherapy
Biological Therapy
Hormone Therapy
and Others

Global Prostate Cancer Treatment Market by Distribution Channel

Market Overview
Hospitals Pharmacies
Drug Stores & Retail Pharmacies
and Online Pharmacies

Global Prostate Cancer Treatment Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Ferring Pharmaceuticals Inc. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline Plc. (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ipsen Pharma (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG. (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Ltd (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celgene Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments